Nilotinib
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Nilotinib: From Chronic Myeloid Leukemia to Dermatofibrosarcoma Protuberans
One-Sentence Summary
Nilotinib is a BCR-ABL/PDGFR/KIT tyrosine kinase inhibitor; this specific original-indication text is not captured in the current Evidence Pack, but the drug is publicly known to have been developed and approved for chronic myeloid leukemia (CML). The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), with no dedicated clinical trials and 1 supporting review article currently available for this specific drug–disease pair.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not captured in this Evidence Pack (data gap, see DG002); generally known to be Chronic Myeloid Leukemia (CML) |
| Predicted New Indication | Dermatofibrosarcoma Protuberans |
| TxGNN Prediction Score | 99.31% |
| Evidence Level | L4 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack (data gap DG002). Based on general pharmacological knowledge, nilotinib is a second-generation tyrosine kinase inhibitor originally developed against BCR-ABL for chronic myeloid leukemia, and it also potently inhibits PDGFR-α/β and KIT — targets that are unrelated to the BCR-ABL fusion driving CML but are shared with several soft-tissue sarcomas.
Dermatofibrosarcoma protuberans is a distinct tumour type driven in most cases by the COL1A1-PDGFB fusion gene, which causes constitutive PDGFR-β activation. Because nilotinib is a PDGFR inhibitor, it is mechanistically plausible that it could suppress this driver alteration, independent of its original CML indication.
The strongest supporting argument is a class-effect precedent: imatinib, a first-generation PDGFR/BCR-ABL/KIT inhibitor closely related to nilotinib, is already an approved and guideline-recommended treatment for DFSP. This establishes that PDGFR blockade is a clinically validated strategy in this tumour, lending biological plausibility to the TxGNN prediction for nilotinib — although no dedicated nilotinib-specific trial or case series in DFSP currently exists in the Evidence Pack.
Clinical Trial Evidence
Currently no related clinical trials registered.
(Note: a Phase 1/2 trial of nilotinib in sarcomas — NCT02587169 — exists but is registered under liposarcoma/leiomyosarcoma, not DFSP; see the drug’s other predicted indications for that evidence.)
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological Research | Reviews the role of small-molecule PDGFR inhibitors — including nilotinib — in treating PDGF-driven neoplastic disorders; supports the mechanistic rationale but provides no DFSP-specific clinical data. |
EU Market Information
No EU marketing authorization data is available for nilotinib in this dataset (0 authorizations, market status: Not marketed). This should be re-verified against the current EMA register, since nilotinib is authorized in the EU under the brand name Tasigna for CML — its absence here likely reflects an incomplete data pull rather than a true market gap.
Cytotoxicity
Nilotinib is an antineoplastic tyrosine kinase inhibitor (targeted therapy class), so this section is included.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (BCR-ABL / PDGFR / KIT tyrosine kinase inhibitor), not conventional cytotoxic chemotherapy |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Important note: TFDA/EMA label warnings and contraindications (DG001) are flagged as a Blocking data gap in this Evidence Pack — the package insert has not yet been retrieved and parsed. This must be resolved before any Stage 1 (S1) safety screening can be completed. Drug interaction data was also queried with no results found (query_status: not_found).
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top prediction (DFSP) is supported only by mechanistic class-effect reasoning and a general PDGFR-inhibitor review article (L4) — there is no clinical trial or case-level evidence for nilotinib specifically in DFSP.
- A Blocking-severity data gap exists on TFDA/EMA safety labeling, which prevents any Stage 1 safety evaluation from being completed.
- EU market authorization status is unresolved (0 licenses recorded), which needs reconciliation before regulatory pathway planning.
To proceed, the following is needed:
- Retrieve and parse the official nilotinib package insert (TFDA/EMA SmPC) to close DG001 and DG002
- Confirm actual EU market/authorization status (likely a data extraction gap given nilotinib’s known EU approval as Tasigna)
- Seek case reports, off-label use data, or a pilot study of nilotinib specifically in DFSP, given the existing imatinib class-effect precedent
- Note: the rank-2 candidate (liposarcoma) already has stronger evidence (L2, a completed Phase 1 trial NCT02587169 and a published Phase 1 paper) and may be a more actionable next candidate to evaluate in parallel
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.